Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis.
Lavoie S, Jack BN, Griffiths O, Ando A, Amminger P, Couroupis A, Jago A, Markulev C, McGorry PD, Nelson B, Polari A, Yuen HP, Whitford TJ. Lavoie S, et al. Among authors: polari a. Schizophr Res. 2018 Jan;191:95-100. doi: 10.1016/j.schres.2017.11.005. Epub 2017 Nov 11. Schizophr Res. 2018. PMID: 29132815
Clinical trajectories in the ultra-high risk for psychosis population.
Polari A, Lavoie S, Yuen HP, Amminger P, Berger G, Chen E, deHaan L, Hartmann J, Markulev C, Melville F, Nieman D, Nordentoft M, Riecher-Rössler A, Smesny S, Stratford J, Verma S, Yung A, McGorry P, Nelson B. Polari A, et al. Schizophr Res. 2018 Jul;197:550-556. doi: 10.1016/j.schres.2018.01.022. Epub 2018 Feb 18. Schizophr Res. 2018. PMID: 29463457
Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
O'Donoghue B, Francey SM, Nelson B, Ratheesh A, Allott K, Graham J, Baldwin L, Alvarez-Jimenez M, Thompson A, Fornito A, Polari A, Berk M, Macneil C, Crisp K, Pantelis C, Yuen HP, Harrigan S, McGorry P. O'Donoghue B, et al. Among authors: polari a. Early Interv Psychiatry. 2019 Aug;13(4):953-960. doi: 10.1111/eip.12716. Epub 2018 Jul 19. Early Interv Psychiatry. 2019. PMID: 30024100 Clinical Trial.
Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
Weller A, Gleeson J, Alvarez-Jimenez M, McGorry P, Nelson B, Allott K, Bendall S, Bartholomeusz C, Koval P, Harrigan S, O'Donoghue B, Fornito A, Pantelis C, Paul Amminger G, Ratheesh A, Polari A, Wood SJ, van der El K, Ellinghaus C, Gates J, O'Connell J, Mueller M, Wunderink L, Killackey E. Weller A, et al. Among authors: polari a. Early Interv Psychiatry. 2019 Dec;13(6):1345-1356. doi: 10.1111/eip.12769. Epub 2018 Nov 29. Early Interv Psychiatry. 2019. PMID: 30488637
Dynamic prediction of transition to psychosis using joint modelling.
Yuen HP, Mackinnon A, Hartmann J, Amminger GP, Markulev C, Lavoie S, Schäfer MR, Polari A, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger G, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, McGorry PD, Nelson B. Yuen HP, et al. Among authors: polari a. Schizophr Res. 2018 Dec;202:333-340. doi: 10.1016/j.schres.2018.07.002. Epub 2018 Jul 7. Schizophr Res. 2018. PMID: 30539771 Clinical Trial.
41 results